Over a 3-year follow-up, the SURMOUNT-1 trial found that treatment with tirzepatide (a dual GLP1/GIP agonist) of patients with obesity and prediabetes led to substantial and sustained weight reduction, with a lower risk of progression to type 2 diabetes
Originating from Gila monster saliva and sharing amino acid similarities with human GLP-1, this drug effectively reduces blood sugar levels and became a landmark addition to diabetes care by offering type 2 diabetes patients an innovative therapeutic option
Acute & Chronic Inflammation There has been growing interest in GLP-1 microdosing for managing both acute and chronic inflammation, particularly in conditions such as PCOS, cardiovascular disease, and even sports performance
Insurance typically covers medical infusions prescribed to treat diagnosed conditions such as iron infusions for anemia
Are protein bars good for weight loss
This is generally beneficial, but combined with foods that already produce rapid glucose spikes (or alcohol), it can create hypoglycaemia in some patients particularly those also on insulin or sulfonylureas